ByQuantisnow· · 3m ago·Wall Street’s wire, on your screen.
Stocks in this Quantisnow insightHealth Care
Wells Fargo initiated Denali Therapeutics (DNLI) at Overweight with a $35.00 price target.
Ask Ellis, your AI research assistant, about this story
What DNLI did after its last 4 analyst coverage notes
Since Jan 2026, DNLI closed higher the next session 2 times and lower 2 times after an analyst coverage note. Past moves show timing only, not that the news caused them.
Core lists each of the 4 with the headline, the next-day move against SPY and where DNLI was five trading days later. $19/mo, 3-day free trial.
Historical context for DNLI
Across the 21 sessions after earlier DNLI headlines, the stock closed higher 9 times and lower 12 times, with a median move of 3.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
Keep researching DNLI
- What is Initiation of coverage?The first research report an analyst or brokerage publishes on a company, setting an opening rating and price target.
- Analyst upgrades and downgradesAn analyst upgrade or downgrade is a change in a sell-side analyst’s stock rating. Learn what Buy, Hold and Sell mean, how price targets work and which changes matter.
- DNLI insider tradesEvery buy and sale reported by Denali Therapeutics Inc. officers, directors and large holders.
- DNLI earnings historyPast Denali Therapeutics Inc. earnings releases, newest first.
- DNLI financial statementsRevenue, profit, cash flow and balance sheet from Denali Therapeutics Inc.’s SEC filings.
Quantisnow market dataNASDAQ
DNLI
Denali Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2017
